A FIXED-SEQUENCE CROSSOVER, DRUG-DRUG INTERACTION STUDY EVALUATING THE EFFECT OF THE CYTOCHROME P450 3A INHIBITOR ITRACONAZOLE ON DNL151 IN HEALTHY SUBJECTS
Latest Information Update: 01 Aug 2021
At a glance
- Drugs DNL-151 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 06 Aug 2020 According to a Denali Therapeutics media release, this trial is anticipated to complete in 2020.
- 06 Aug 2020 According to a Denali Therapeutics media release, the company has competed dosing of 162 healthy volunteers in this study and is completing further dose escalation cohorts to define the full therapeutic window of the molecule.
- 02 Apr 2020 According to a Denali Therapeutics media release, Denali is analyzing available data from this trials and is on track to select either DNL201 or DNL151 by mid-2020 to progress into Phase 2/3 trials.